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Over the last decade, it has become clear that the role of angiotensin II extends far beyond recognized renal and
cardiovascular effects. The presence of an autologous renin-angiotensin system has been demonstrated in almost
all tissues of the body. It is now known that angiotensin II acts both independently and in synergy with TGF-beta
to induce fibrosis via the angiotensin type 1 receptor (AT1) in a multitude of tissues outside of the cardiovascular
and renal systems, including pulmonary fibrosis, intra-abdominal fibrosis, and systemic sclerosis. Interestingly, recent
studies have described a paradoxically regenerative effect of the angiotensin system via stimulation of the angiotensin
type 2 receptor (AT2). Activation of AT2 has been shown to ameliorate fibrosis in animal models of skeletal muscle,
gastrointestinal, and neurologic diseases. Clinical reports suggest a beneficial role for modulation of angiotensin
II signaling in cutaneous scarring. This article reviews current knowledge on the role that angiotensin II plays in
tissue fibrosis, as well as current and potential therapies targeting this system.Review
Angiotensin II (AngII) has long been recognized as the
principal vasoactive mediator of the renin-angiotensin
system (RAS). Over the past 20 years, however, it has
become clear that effects of AngII extend beyond sys-
temic cardiovascular and renal actions. Once believed to
act only as a circulating hormone, it is now evident that
a local ‘tissue RAS’ exists in almost all organs and tis-
sues, including the heart [1], blood vessels [2], brain [2],
kidney [2], fat [3], liver [4], and skin [5]. Tissue RASs are
functionally autonomous systems that have been shown
to play an important role in the development of fibrosis
[6,7]. The following is a review of the role of AngII in fi-
brotic disorders, from cellular signaling to clinical cor-
relation, and potential therapies aimed at modulating the
angiotensin pathway beyond the cardiovascular and
renal systems.General mechanisms of fibrosis
The mammalian response to injury occurs in three dis-
tinct phases [8]. The initial inflammatory phase occurs
immediately following insult and involves activation of* Correspondence: mbezuhly@dal.ca
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unless otherwise stated.the coagulation cascade, fibrin deposition, and infiltra-
tion of macrophages and neutrophils [9]. Following this,
the proliferative phase is defined by angiogenesis, fibro-
blast proliferation, and differentiation [10,11]. Finally, in
the remodeling phase, fibroblasts and myofibroblasts de-
posit a collagen-rich extracellular matrix that will ultim-
ately become a scar that replaces the injured functional
tissue. This process of healing is highly conserved across
tissue types.
Fibrosis also occurs ubiquitously throughout the body
as a pathologic response to chronic tissue injury and is
essentially a persistence of the normal wound healing re-
sponse. It is characterized by chronic inflammation and
persistence of myofibroblasts ultimately resulting in ex-
cess accumulation of extracellular matrix and destruc-
tion of the normal tissue architecture. Fibrogenesis is
most likely triggered by inflammation, whether or not
inflammation leads to tissue repair or to fibrosis depend-
ing on the balance between extracellular matrix (ECM)
synthesis and degradation [12]. In response to chronic
tissue damage, ECM-producing cells, namely fibroblasts,
undergo a process of activation characterized by prolifer-
ation and differentiation into myofibroblasts, which are
the main cellular effectors of fibrosis [13]. These cells
deposit large amounts of ECM proteins and express the
contractile protein α-smooth muscle actin (α-SMA),
which contributes to the decreased tissue compliancel. This is an Open Access article distributed under the terms of the Creative
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eral soluble factors including cytokines, growth factors, and
products of oxidative stress [14,15]. Although several mole-
cules are involved in this process, transforming growth
factor-beta 1 (TGF-β1) plays a pivotal role in triggering and
sustaining fibrogenesis [16].
Renin-angiotensin system
In the classical description, decreased renal perfusion re-
sults in renin release from the juxtaglomerular cells of
the kidney. This enzyme then cleaves angiotensinogen,
produced in the liver, to angiotensin I which is subse-
quently converted to angiotensin II by angiotensin-con-
verting enzyme (ACE) in the lung. AngII acts
systemically to regulate blood pressure as well as water
and electrolyte homeostasis [17].
We now know that AngII is expressed and acts on al-
most all tissues. AngII signals through two main recep-
tors, angiotensin receptor 1 (AT1) and angiotensin
receptor 2 (AT2) [7]. AT1 mediates the ‘classical’ effects
of AngII, namely regulation of blood pressure as well as
sodium and water homeostasis. Locally, AT1 activation
stimulates profibrotic downstream effects, namely in-
flammatory cell recruitment, angiogenesis, cellular pro-
liferation, and accumulation of ECM [6,7].
Until recently, the role of AT2 was less well defined;
however, recent research has revealed that AT2 recep-
tor stimulation counteracts the harmful effects of AT1
signaling in fibrotic disease [18-20]. The so-called ‘pro-
tective arm’ of RAS has expanded to include the hepta-
peptide angiotensin 1 to 7 (Ang1-7), its receptor, Mas,
and angiotensin-converting enzyme 2 (ACE2), which
produces Ang1-7 from both AngI and AngII [21,22].
Activation of these counterregulatory systems has been
shown to decrease inflammation, cell proliferation, and
collagen deposition [21,23] and improve healing in ex-
perimental models of the cardiovascular, renal, im-
munologic, and neurologic systems [24]. Although
studies have shown that both AT1 and AT2 receptors
are upregulated after injury [23], the interplay between
the two remains to be elucidated, particularly with re-
gard to AT2. At present, mechanisms responsible for
the regenerative effects associated with AT2 remain
unclear. There is evidence that the anti-inflammatory
effects of AT2 are in part related to inhibition of NF-
κΒ-mediated transcription of inflammatory mediators;
however, the downstream signaling effects remain a
focus of ongoing research [19].
Angiotensin-TGF-β signaling
Despite the reported anti-inflammatory effects of the
AT2 and Mas counter-regulatory systems, current re-
search has continued to focus on the predominantly pro-
fibrotic role of AngII. The fibrogenic effects of AngIIhave been linked to its activation of TGF-β1 signaling
(Figure 1) [25-27]. The TGF-β family has been exten-
sively studied and is known to be involved in a variety of
cellular functions, both physiologic and pathologic [28].
They are known to critically regulate tissue homeostasis
and repair, immune and inflammatory responses, ECM
deposition, cell differentiation and growth [29,30]. In
mammals, three isoforms exist, designated TGF-β1,
TGF-β2, and TGF-β3, with TGF-β1 being the most
prevalent and expressed in almost all tissues [30]. Over-
expression of TGF-β1 has been established as a key con-
tributor to fibrosis in almost all tissues [16,25]. It
potently stimulates myofibroblast differentiation and
synthesis of ECM proteins [31]. TGF-β1 also acts to pre-
serve ECM proteins by inhibiting the activity of matrix
metalloproteinases (MMPs) and inducing synthesis of
tissue inhibitor metalloproteinases (TIMPs) [32]. Add-
itionally, it strongly induces connective tissue growth
factor (CTGF), a critical profibrotic mediator implicated
in fibroblast proliferation, cellular adhesion, and ECM
synthesis [33].
TGF-β1 is secreted as a latent precursor, bound to
TGF-β1 latency-associated peptide (LAP), and requires
proteolytic cleavage to become active [34]. Significant
amounts of latent TGF-β1 are stored in the ECM of
most tissues; however, activation of just a small fraction
of latent TGF-β1 elicits maximal cellular response [35].
Following activation, TGF-β1 binds to the TGF-β1 type
II receptor (TβRII), which subsequently complexes with
and transphosphorylates the TGF-β1 type I receptor
(TβRI), also known as ALK5 [36]. Active TβRI in turn
activates the intracellular Smad signaling cascade by
phosphorylating Smad2 and Smad3. Smad2 and Smad3
complex with Smad4 and translocate to the nucleus
where they activate genes which code for extracellular
matrix proteins including type I collagen and fibronec-
tin. Activation of Smad3 also induces expression of
Smad7, which inhibits TGF-β1-mediated effects, forming
a negative feedback loop [30].
In addition to activation of Smad signaling, TGF-β1 can
also activate several noncanonical mitogen-activated pro-
tein kinase pathways, namely extracellular signal-related
kinase (ERK), p38 MAPK, and c-Jun-N-terminal kinase
(JNK) [37,38]. These signaling cascades are activated in re-
sponse to extracellular mitogenic and stress stimuli and act
to further regulate Smad signaling as well as differentiation,
proliferation, cell survival, and apoptosis. Activation of ERK
has been shown to increase [39] or decrease [40] Smad sig-
naling depending on the cell type. Conversely, activation of
p38 MAPK and JNK typically potentiates TGF-β/Smad ef-
fects [41,42]. TGF-β also induces G0/G1 cell cycle arrest in-
dependent of Smad proteins via p38 MAPK [43] and has
been shown to activate PI3 kinase/Akt, c-Abl, and Rho
GTPase signaling cascades [37].
Figure 1 Angiotensin II, transforming growth factor-β, and Smad signaling pathways. Binding of angiotensin II (AngII) to the angiotensin type 1
receptor (AT1) results in Smad2 and Smad3 phosphorylation via the ERK/p38/MAPK pathway. Activated Smad2 and Smad3 complex with Smad4
and translocate into the nucleus resulting in transcription of target genes including transforming growth factor-β (TGF-β), procollagen I, procollagen III,
and fibronectin. AngII-AT1 binding also directly activates TGF-β, which in turn activates Smad signaling in a similar manner. The P-Smad2/3-Smad4 complex
induces transcription of Smad7, which has an inhibitory effect on TGF-β by targeting TGF-β receptor I (TGF-βR1) and Smads for ubiquitin-dependent
degradation. Smad7 also inhibits NF-κB-driven inflammation via induction of the NF-κB inhibitor, IκBα. Conversely, activation of the AngII type 2 receptor
(AT2) signaling has an inhibitory effect on both Smad and MAPK signaling pathways via dephosphorylating actions of phosphotyrosine phosphatase and
protein phosphatase 2A. This produces antiproliferative and survival-promoting effects that oppose AT1-mediated fibrotic changes. Green lines indicate
positive regulation. Red lines indicate negative regulation. Latent TGF-β binding protein (LTBP), TGF-β receptor 2 (TGF-βIIR), thrombospondin-1 (TSP-1),
extracellular signal-relate kinase (ERK), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), inhibitor of kappa B alpha (IκBα), protein serine/
threonine phosphatase 2A (PP2A), phosphotyrosine phosphatase (PTP).
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tion is less well defined, there is evidence that AT2 ac-
tivation results in attenuation of both canonical
(Smad-dependent) and noncanonical (MAPK) TGF-β1
signaling cascades, particularly ERK signaling [44].Angiotensin II and AT1 expression in fibrosis outside the
heart and kidney
Both AT1 and AT2 have been shown to be upregulated
after injury in the heart [45], blood vessels [46], brain[47], nerves [48], and skin [5]. This occurs as early as
24 h after injury and persists for up to 3 months [23].
Enhanced signaling of AngII via AT1 in injured tissue
has been established in cardiovascular and renal disease
as well as Alzheimer’s, Parkinson’s, and stroke [20,45,49].
Additionally, AngII blockade by angiotensin-converting en-
zyme inhibitors (ACEIs) or AngII receptor blockers (ARBs)
has been shown to significantly improve or reverse fibrosis
in the skeletal muscle, heart, kidney, liver, and lung [50-55].
Angiotensin II-mediated AT1 activation has been
shown to play an important role in the development of
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that the transition of normal lung fibroblasts to myofi-
broblasts by TGF-β1 in vitro is accompanied by robust
expression of angiotensin mRNA, protein, and AngII
peptide [56]. In addition, the increased contractility of
lung fibroblasts isolated from fibrotic lungs has been
shown to be dependent on angiotensin signaling [57].
Paizis et al. demonstrated that following liver injury,
there is a marked increase in AT1 localized to areas of
active fibrogenesis [58]. Expression of AT1 has been doc-
umented on activated, but not quiescent, hepatic stellate
cells which are the key mediator of hepatic fibrosis, sug-
gesting an important role of RAS in chronic liver disease
[4]. Suekane et al. conducted a phenotypic analysis of
colonic strictures isolated from Crohn’s patients and
found that the fibromuscular cells accumulated within
strictures strongly expressed AT1 [59].
In 2005, Steckelings et al. characterized the distribu-
tion of angiotensin receptor within normal and wounded
human skin [23]. In normal, unwounded skin, AT1 and
AT2 receptors are expressed on keratinocytes through-
out the epidermis but not on dermal fibroblasts, despite
the fact that both cell types have comparable levels of
mRNA for both receptor subtypes. After wounding, AT1
and AT2 are upregulated in both epidermis and dermis
within 48 h and persist within the scar for up to
3 months.
Hypertrophic scars, keloids, and scleroderma are
pathologic fibrotic cutaneous conditions. Although his-
tologically distinct, they all demonstrate increased ex-
pression of TGF-β1 and AngII activity [60-62]. Patients
with diffuse cutaneous systemic sclerosis (SSc) have sig-
nificantly elevated serum levels of AngII and cutaneous
angiotensinogen expression, which is not expressed in
healthy skin [62]. In fact, subcutaneous infusion of AngII
has been shown to induce dermal fibrosis in mice, opening
up potential for a novel animal model of skin fibrosis [63].
Antifibrotic effects of AT1 inhibition
As previously stated, AngII exerts profibrotic effects via
AT1 receptor signaling. Over nearly three decades, re-
search has established the therapeutic efficacy of RAS
blockade for management of hypertension, heart failure,
and renal disease. The body of research focusing on tar-
geting AngII in cardiac and renal fibrosis is extensive,
and several thorough reviews have been written on this
topic [64-66].
Experimental and clinical studies have provided evi-
dence that targeting angiotensin may be of therapeutic
benefit in the management of pulmonary fibrosis. In ani-
mal models, inhibition of AT1 signaling has been shown
to attenuate experimental pulmonary fibrosis induced by
bleomycin [67], radiation [68], and hyperoxia [69]. In a
pilot clinical study, Couluris et al. evaluated the effectlosartan, an AT1 antagonist, on idiopathic pulmonary fi-
brosis progression over 12 months [34]. Preliminary data
demonstrated stable or improved pulmonary function
testing in 12 of the 17 patients treated with losartan.
The authors concluded that losartan is a promising low-
toxicity agent for treatment of idiopathic pulmonary fi-
brosis that requires more extensive evaluation in a
placebo-controlled multicenter trial.
The literature also supports a beneficial effect of
ACEI/ARBs in preventing or attenuating peritoneal fi-
brosis that occurs in long-term peritoneal dialysis pa-
tients [70]. Recently, losartan was shown to improve
fibrosis in a rat model of Crohn’s disease [71]. Despite
the large number of animal studies, there is a relative
paucity of clinical data. There have been a number of
small prospective human studies that have demonstrated
a benefit of ACEI/ARB therapy in the treatment of liver
fibrosis associated with hepatitis C [69-73]. While a
number of clinical studies have demonstrated decreased
liver fibrosis with losartan therapy [74,75], the multicen-
ter HALT-C trial showed no significant reduction in the
liver fibrosis score in patients on ACEI/ARB therapy
[76]. This finding runs counter to the majority of avail-
able literature. As suggested by the authors of a recent
review on the subject [77], the finding of the HALT-C
analysis may be attributable to an increased proportion
of diabetics in the ACEI/ARB treatment, a population
known to experience more rapid progression of hepatitis
C infection.
The potential role of ARB and ACEI in managing cu-
taneous fibrosis has not been extensively investigated.
Marut et al. reported decreased Smad2/3, collagen con-
centration, and α-SMA expression in a mouse model of
systemic sclerosis among animals treated with the ARB
irbesartan [78]. In the clinical literature, a handful of
case reports describe a subjective incidental improve-
ment in the appearance of keloids or hypertrophic scars
following initiation of ACEI or ARB therapy for hyper-
tension [79,80]. Uzun et al. recently compared the effect
the oral ACEI enalapril with intralesional triamcinolone
in a rabbit ear hypertrophic scar model [81]. They found
a modest reduction in scar elevation index in the enala-
pril group, with a greater reduction in the steroid group.
A number of animal studies have examined the effect
of AngII blockade on skeletal muscle fibrosis. Losartan
has been shown to reduce fibrosis and restore skeletal
muscle strength in animal models of congenital muscu-
lar dystrophy and Marfan syndrome, primarily via inhib-
ition of TGF-β1 signaling [55,82]. AT1 blockade was also
shown to improve muscle regeneration after injury in a
mouse gastrocnemius laceration model [83]. Although
encouraging, many of these studies employed dosages
that were well in excess of the human equivalent dose
prescribed for hypertension management [55,83]. To this
Murphy et al. Fibrogenesis & Tissue Repair  (2015) 8:7 Page 5 of 7end, the clinical practicality of AT1 blockade for treat-
ment of muscle injury remains unclear.Antifibrotic effects of AT2 and ACE2/Ang-(1-7)/Mas axis
stimulation
Currently, much of the research attention regarding
angiotensin has been devoted to exploring function of
AT2 and the Mas receptor, which, along with ACE2
and angiotensin 1 to 7, comprise the protective arm of
the RAS. The recent availability of specific AT2 ago-
nists has provided greater momentum in this area,
with a number of drugs currently in preclinical or
clinical development [18,24].
Stimulation of the ACE2/Ang-(1-7)/Mas axis has been
shown to protect against bleomycin-induced pulmonary
fibrosis, aspiration-induced lung injury, and severe acute
respiratory syndrome (SARS) [84-86]. Wagenaar et al.
demonstrated that agonists of Mas and AT2 protect
against cardiopulmonary disease in rats with neonatal
hyperoxia-induced lung injury [87]. Fibroblasts isolated
from human fibrotic lung produce significantly more
collagen in vitro when compared to normal fibroblasts.
Uhal et al. demonstrated that this phenomenon is abol-
ished by administration of an ARB [88].
Ang-(1-7) has also been shown to play a protective
role in hepatic fibrosis [89]. Infusion of Ang-(1-7) has
been shown to reduce fibrosis and proliferation by inhi-
biting activation of hepatic stellate cells, which are a
major fibrogenic cell type in the liver [90].
In skeletal muscle, Ang-(1-7) was shown to decrease
fibrosis and increase muscle strength in an animal model
of muscular dystrophy [91]. Morales et al. recently dem-
onstrated that this effect was related to attenuation of
AngII-induced TGF-β1 expression by Ang-(1-7)/Mas
activation [92].
AT2 signaling has garnered considerable attention for
its potential role in improving peripheral nerve regener-
ation. Both AT1 and AT2 receptors are expressed on
Schwann cells [93], with a dramatic upregulation of
AT2 expression observed following injury [94]. Subse-
quent animal experiments demonstrated that AT2
stimulation accelerates axonal regeneration and myelin-
ation [94,95]. In addition, the axonal recovery resulted
in gain of function in a sciatic nerve injury model in
the rat [94]. Most recently, AT2 stimulation has been
shown to have a beneficial effect in a mouse spinal cord
injury model [96].
The beneficial effects of AT2 stimulation have also
been demonstrated in models of stroke and
Alzheimer’s [97], McCarthy et al. demonstrated that
AT2 stimulation in a rat prior to stroke reduced the
severity of neuronal injury in a dose-dependent
manner [98].Conclusions
The presence of an autologous renin-angiotensin system
extends beyond the classically recognized renal and car-
diovascular systems and has been demonstrated in al-
most all tissues of the body. It is now recognized that
AngII acts both independently and in synergy with TGF-
β to induce fibrosis via the AT1 in a multitude of condi-
tions including tubulointerstitial nephritis, myocardial
infarction, and systemic sclerosis. Interestingly, recent
research has described a paradoxically regenerative effect
of the angiotensin system via stimulation of AT2. Activa-
tion of AT2 has been shown to ameliorate fibrosis in ani-
mal models of cardiovascular, renal, and neurologic
diseases. Manipulation of AngII signaling via AT1 block-
ade and AT2 stimulation represent promising thera-
peutic approaches for inhibiting tissue fibrosis.
Abbreviations
AngII: Angiotensin II; RAS: Renin-angiotensin system; ECM: Extracellular
matrix; α-SMA: Alpha-smooth muscle actin; TGF-β: Transforming growth
factor-beta; ACE: Angiotensin-converting enzyme; AT1: Angiotensin II type 1
receptor; AT2: Angiotensin II type 2 receptor; Ang1-7: Angiotensin (1-7); NF-
κB: Nuclear factor kappa-light-chain-enhancer of activated B cells;
MMP: Matrix metalloproteinase; TIMPs: Tissue inhibitor metalloproteinase;
CTGF: Connective tissue growth factor; LAP: Latency-associated peptide;
TβRII: TGF-β1 type II receptor; TβRI: TGF-β1 type I receptor; ERK: Extracellular
signal-related kinase; JNK: c-Jun-N-terminal kinase; ARBs: AngII receptor
blockers; ACEi: Angiotensin-converting enzyme inhibitor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM designed the concept, carried out the literature search, and drafted the
manuscript. AW designed the figure, participated in the literature search, and
helped draft the manuscript. MB performed an independent literature search
and helped draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was funded by an IWK Health Center Establishment Grant (MB)
and through the Nova Scotia Ministry of Health (AM).
Received: 8 September 2014 Accepted: 6 March 2015
References
1. Lindpaintner K, Jin M, Wilhelm MJ, Suzuki F, Linz W, Schoelkens BA, et al.
Intracardiac generation of angiotensin and its physiologic role. Circulation.
1988;77:I18–23.
2. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue
renin-angiotensin systems: new insights from experimental animal
models in hypertension research. J Mol Med (Berl). 2001;79:76–102.
3. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the
adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270–7.
4. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, et al.
Activated human hepatic stellate cells express the renin-angiotensin
system and synthesize angiotensin II. Gastroenterology. 2003;125:117–25.
5. Steckelings UM, Wollschläger T, Peters J, Henz BM, Hermes B, Artuc M.
Human skin: source of and target organ for angiotensin II. Exp Dermatol.
2004;13:148–54.
6. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling
and function. Blood Press. 2003;12:70–88.
7. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union
of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev.
2000;52:415–72.
Murphy et al. Fibrogenesis & Tissue Repair  (2015) 8:7 Page 6 of 78. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738–46.
9. Clark RA, Lanigan JM, DellaPelle P, Manseau E, Dvorak HF, Colvin RB.
Fibronectin and fibrin provide a provisional matrix for epidermal cell
migration during wound reepithelialization. J Invest Dermatol. 1982;79:264–9.
10. Witte M, Barbul A. General principles of wound healing. Surg Clin North Am.
1997;77:509–28.
11. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular
endothelial growth factor mediates angiogenic activity during the
proliferative phase of wound healing. Am J Pathol. 1998;152:1445–52.
12. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and
inflammatory bowel disease: cellular mediators and animal models. Am
J Physiol Gastrointest Liver Physiol. 2000;279:G653–9.
13. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat M-L, Gabbiani G.
The myofibroblast: one function, multiple origins. Am J Pathol.
2007;170:1807–16.
14. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress
in basic and clinical science. CurrOpinGastroenterol. 2008;24:462–8.
15. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB.
Myofibroblasts. I. Paracrine cells important in health and disease. Am
J Physiol. 1999;277:C1–9.
16. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis.
Growth Factors. 2011;29:196–202.
17. Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol.
2003;24:27–39.
18. Bader M, Santos RA, Unger T, Steckelings UM. New therapeutic pathways in
the RAS. J Renin Angiotensin Aldosterone Syst. 2012;13:505–8.
19. Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C,
et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory
through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.
Hypertension. 2010;55:924–31.
20. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II
AT2 receptor inhibits proliferation and promotes differentiation in PC12W
cells. Mol Cell Endocrinol. 1996;122:59–67.
21. Sumners C, Horiuchi M, Widdop RE, McCarthy C, Unger T, Steckelings UM.
Protective arms of the renin-angiotensin-system in neurological disease. Clin
Exp Pharmacol Physiol. 2013;40:580–8.
22. Santos RAS, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting
enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin
system. J Endocrinol. 2013;216:R1–R17.
23. Steckelings UM, Henz BM, Wiehstutz S, Unger T, Artuc M. Differential
expression of angiotensin receptors in human cutaneous wound healing.
Br J Dermatol. 2005;153:887–93.
24. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists:
hypertension and beyond. Curr Opin Nephrol Hypertens. 2012;21:142–6.
25. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor
(TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–6.
26. Schultz JEJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-beta1
mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.
J Clin Invest. 2002;109:787–96.
27. Sun Y, Zhang J, Zhang JQ, Ramires FJA. Local angiotensin II and
transforming growth factor-beta1 in renal fibrosis of rats. Hypertension.
2000;35:1078–84.
28. Gabriel VA. Transforming growth factor-beta and angiotensin in fibrosis and
burn injuries. J Burn Care Res. 2009;30:471–81.
29. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory
axis in the tumor microenvironment and progression. Trends Immunol.
2010;31:220–7.
30. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and
gene regulation: consequences for extracellular matrix remodeling and
wound healing. J Dermatol Sci. 2004;35:83–92.
31. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth
factor-beta 1 induces alpha-smooth muscle actin expression in granulation
tissue myofibroblasts and in quiescent and growing cultured fibroblasts.
J Cell Biol. 1993;122:103–11.
32. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis.
Methods Mol Med. 2005;117:69–80.
33. Rupérez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M.
Connective tissue growth factor is a mediator of angiotensin II-induced
fibrosis. Circulation. 2003;108:1499–505.
34. Koli K, Saharinen J, Hyytiäinen M, Penttinen C, Keski-Oja J. Latency, activation,
and binding proteins of TGF-β. Microsc Res Tech. 2001;52:354–62.35. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation.
J Cell Sci. 2003;116:217–24.
36. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol.
2000;1:169–78.
37. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways
in TGF-beta family signalling. Nature. 2003;425:577–84.
38. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128–39.
39. Funaba M, Zimmerman CM, Mathews LS. Modulation of Smad2-mediated
signaling by extracellular signal-regulated kinase. J Biol Chem.
2002;277:41361–8.
40. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression
of TGF b / Smad signaling by oncogenic Ras. Genes Dev.
1999;13:804–16.
41. Furukawa F, Matsuzaki K, Mori S, Tahashi Y, Yoshida K, Sugano Y, et al. p38
MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat
myofibroblasts. Hepatology. 2003;38:879–89.
42. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, et al.
Transforming growth factor-β and platelet-derived growth factor signal via
c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic
stellate cells after acute liver injury. Am J Pathol. 2005;166:1029–39.
43. Seay U, Sedding D, Krick S, Hecker M, Seeger W, Eickelberg O. Transforming
growth factor - NL-dependent growth inhibition in primary vascular smooth
muscle cells is p38-dependent. 2005, 315:1005–1012.
44. Habashi J, Doyle J, Holm T, Aziz H, Schoenhoff F, Bedja D, et al. Angiotensin
II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK
antagonism. Science. 2011;332:361–6.
45. Busche S, Gallinat S, Bohle RM, Reinecke A, Seebeck J, Franke F, et al.
Expression of angiotensin AT(1) and AT(2) receptors in adult rat
cardiomyocytes after myocardial infarction. A single-cell reverse
transcriptase-polymerase chain reaction study. Am J Pathol.
2000;157:605–11.
46. Viswanathan M, Strömberg C, Seltzer A, Saavedra JM. Balloon angioplasty
enhances the expression of angiotensin II AT1 receptors in neointima of rat
aorta. J Clin Invest. 1992;90:1707–12.
47. Makino I, Shibata K, Ohgami Y, Fujiwara M, Furukawa T. Transient
upregulation of the AT2 receptor mRNA level after global ischemia in the
rat brain. Neuropeptides. 1996;30:596–601.
48. Gallinat S, Yu M, Dorst A, Unger T, Herdegen T. Sciatic nerve transection
evokes lasting up-regulation of angiotensin AT2 and AT1 receptor mRNA in
adult rat dorsal root ganglia and sciatic nerves. Brain Res Mol Brain Res.
1998;57:111–22.
49. Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer’s
and Parkinson's diseases. Front Endocrinol (Lausanne). 2013;4:158.
50. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H. Combined angiotensin
and endothelin receptor blockade attenuates adverse cardiac remodeling
post-myocardial infarction in the rat: possible role of transforming growth
factor beta(1). J Mol Cell Cardiol. 2001;33:969–81.
51. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al.
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse
model of human hypertrophic cardiomyopathy. Circulation.
2001;103:789–91.
52. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor block-
ade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis.
2002;39:486–92.
53. Boffa J-J, Lu Y, Placier S, Stefanski A, Dussaule J-C, Chatziantoniou C. Regression of
renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism
and matrix metalloproteinases. J Am Soc Nephrol. 2003;14:1132–44.
54. Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment
of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung.
2012;190:523–7.
55. Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, et al.
Losartan, a therapeutic candidate in congenital muscular dystrophy: studies
in the dy(2 J) /dy(2 J) mouse. Ann Neurol. 2012;71:699–708.
56. Abdul-Hafez A, Shu R, Uhal BD. JunD and HIF-1α mediate transcriptional
activation of angiotensinogen by TGF-β1 in human lung fibroblasts. FASEB
J. 2009;23:1655–62.
57. Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in
pulmonary fibrosis. Int J Biochem Cell Biol. 2012;44:465–8.
58. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation
of components of the renin-angiotensin system in the bile duct-ligated rat liver.
Gastroenterology. 2002;123:1667–76.
Murphy et al. Fibrogenesis & Tissue Repair  (2015) 8:7 Page 7 of 759. Suekane T, Ikura Y, Watanabe K, Arimoto J, Iwasa Y, Sugama Y, et al.
Phenotypic change and accumulation of smooth muscle cells in strictures
in Crohn’s disease: relevance to local angiotensin II system. J Gastroenterol.
2010;45:821–30.
60. Zhang K, Garner W, Cohen L, Rodriguez J, Phan S. Increased types I and III
collagen and transforming growth factor-beta 1 mRNA and protein in
hypertrophic burn scar. J Invest Dermatol. 1995;104:750–4.
61. Tang H-T, Cheng D-S, Jia Y-T, Ben D-F, Ma B, Lv K-Y, et al. Angiotensin II
induces type I collagen gene expression in human dermal fibroblasts
through an AP-1/TGF-beta1-dependent pathway. Biochem Biophys Res
Commun. 2009;385:418–23.
62. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, et al.
Angiotensin II in the lesional skin of systemic sclerosis patients contributes
to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum.
2004;50:216–26.
63. Stawski L, Han R, Bujor AM, Trojanowska M. Angiotensin II induces skin
fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther.
2012;14:R194.
64. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7)
balance in cardiac and renal injury. Curr Hypertens Rep. 2014;16:420.
65. Wysocki J, González-Pacheco FR, Batlle D. Angiotensin-converting enzyme
2: Possible role in hypertension and kidney disease. Curr Hypertens Rep.
2008;10:70–7.
66. Batlle D, Soler MJ, Wysocki J. New aspects of the renin-angiotensin system:
angiotensin-converting enzyme 2 - a potential target for treatment of
hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens.
2008;17:250–7.
67. Meng Y, Li X, Cai S-X, Tong W-C, Cheng Y-X. Perindopril and losartan attenuate
bleomycin A5-induced pulmonary fibrosis in rats. Nan Fang Yi Ke Da Xue Xue
Bao. 2008;28:919–24.
68. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, et al. Control
of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting
enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat
Biol. 2000;76:523–32.
69. Li J-J, Xue X-D. Protection of captopril against chronic lung disease induced
by hyperoxia in neonatal rats. Zhongguo Dang Dai Er Ke Za Zhi.
2007;9:169–73.
70. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT. A positive
effect of AII inhibitors on peritoneal membrane function in long-term PD
patients. Nephrol Dial Transplant. 2009;24:272–7.
71. Wengrower D, Zanninelli G, Latella G, Necozione S, Metanes I, Israeli E, et al.
Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis
in rats. Can J Gastroenterol. 2012;26:33–9.
72. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Combination
of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril,
attenuates the murine liver fibrosis development. Liver Int.
2005;25:153–61.
73. Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, et al. Interferon
augments the anti-fibrotic activity of an angiotensin-converting enzyme
inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol.
2006;12:6786–91.
74. Colmenero J, Bataller R, Sancho-Bru P, Domínguez M, Moreno M, Forns X,
et al. Effects of losartan on hepatic expression of nonphagocytic NADPH
oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J
Physiol Gastrointest Liver Physiol. 2009;297:G726-34.
75. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan
administration on liver fibrosis in chronic hepatitis C patients: a pilot study.
World J Gastroenterol WJG. 2005;11:7560–3.
76. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin
blocking agents on the progression of liver fibrosis in the HALT-C Trial
cohort. Dig Dis Sci. 2011;56:564–8.
77. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects
of the renin-angiotensin system in liver disease: clinical implications and
new therapeutic options. Clin Sci (Lond).
2012;123:225–39.
78. Marut W, Kavian N, Servettaz A, Hua-Huy T, Nicco C, Chéreau C, et al.
Amelioration of systemic fibrosis in mice by angiotensin II receptor
blockade. Arthritis Rheum. 2013;65:1367–77.
79. Iannello S, Milazzo P, Bordonaro F, Belfiore F. Low-dose enalapril in the treatment
of surgical cutaneous hypertrophic scar and keloid - two case reports and
literature review. MedGenMed. 2006;8:60.80. Ardekani GS, Aghaei S, Nemati MH, Handjani F, Kasraee B. Treatment of a
postburn keloid scar with topical captopril: report of the first case. Plast
Reconstr Surg. 2009;123:112e–3e.
81. Uzun H, Bitik O, Hekimoğlu R, Atilla P, Kaykçoğlu AU. Angiotensin-converting
enzyme inhibitor enalapril reduces formation of hypertrophic scars in a rabbit
ear wounding model. Plast Reconstr Surg. 2013;132:361e–71e.
82. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al.
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure
of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204–10.
83. Bedair HS, Karthikeyan T, Quintero A, Li Y, Huard J. Angiotensin II receptor
blockade administered after injury improves muscle regeneration and
decreases fibrosis in normal skeletal muscle. Am J Sports Med.
2008;36:1548–54.
84. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting
enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–6.
85. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of
angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung
injury. Nat Med. 2005;11:875–9.
86. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, et al. The
angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers
cardiopulmonary protection against lung fibrosis and pulmonary
hypertension. Am J Respir Crit Care Med. 2010;182:1065–72.
87. Wagenaar GTM, Laghmani EH, Fidder M, Sengers RMA, de Visser YP, de Vries
L, et al. Agonists of MAS oncogene and angiotensin II type 2 receptors
attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced
lung injury. Am J Physiol Lung Cell Mol Physiol. 2013;305:L341–51.
88. Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-beta 1 crosstalk in
human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts
and macrophages. Curr Pharm Des. 2007;13:1247–56.
89. De Macêdo SM, Antunes Guimarães T, Feltenberger JD, Santos SHS. The role
of renin-angiotensin system modulation on treatment and prevention of
liver diseases. Peptides. 2014;62C:189–96.
90. Pereira RM, Dos Santos RAS, Teixeira MM, Leite VHR, Costa LP, da Costa Dias
FL, et al. The renin-angiotensin system in a rat model of hepatic fibrosis:
evidence for a protective role of Angiotensin-(1-7). J Hepatol.
2007;46:674–81.
91. Acuña MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, et al. Restoration
of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition
of TGF-β signalling. Hum Mol Genet. 2014;23:1237–49.
92. Morales MG, Abrigo J, Meneses C, Simon F, Cisternas F, Rivera JC, et al. The
Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-β1
induced by AngII in mouse skeletal muscle. Clin Sci (Lond).
2014;127:251–64.
93. Bleuel A, de Gasparo M, Whitebread S, Püttner I, Monard D. Regulation of
protease nexin-1 expression in cultured Schwann cells is mediated by
angiotensin II receptors. J Neurosci. 1995;15:750–61.
94. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T.
Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo:
role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J.
2003;17:2094–6.
95. Lucius BR, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. Axonal
regeneration in the optic nerve of adult rats. J Exp Med. 1998;188:661–70.
96. Namsolleck P, Boato F, Schwengel K, Paulis L, Matho KS, Geurts N, et al.
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury
by upregulating BDNF expression. Neurobiol Dis. 2013;51:177–91.
97. Jing F, Mogi M, Sakata A, Iwanami J, Tsukuda K, Ohshima K, et al. Direct
stimulation of angiotensin II type 2 receptor enhances spatial memory.
J Cereb Blood Flow Metab. 2012;32:248–55.
98. McCarthy CA, Vinh A, Callaway JK, Widdop RE. Angiotensin AT2 receptor
stimulation causes neuroprotection in a conscious rat model of stroke.
Stroke. 2009;40:1482–9.
